Aggrey Ambali's scientific contributions

Publications (10)

Article
Sub-Saharan Africa, which has a population of more than 1 billion people, carries 24% of the global burden of disease and spends the least on health care of any region, relying heavily on international development assistance to deliver health care for HIV, tuberculosis, and malaria. The demographic and epidemiological transitions occurring in sub-S...
Article
Full-text available
African countries face key challenges in the deployment of GM crops due to incongruities in the processes for effective and efficient commercial release while simultaneously ensuring food and environmental safety. Against the backdrop of the preceding scenario, and for the effective and efficient commercial release of GM crops for cultivation by fa...
Article
Full-text available
A new set of breeding techniques, referred to as New Breeding Techniques developed in the last two decades have potential for enhancing improved productivity in crop and animal breeding globally. These include site directed nucleases based genomic editing procedures-CRISPR and Cas associated proteins, Zinc Finger Nucleases, Meganucleases/Homing End...
Article
Full-text available
Independent, science-based regulation of medical products is a critical part of ensuring quality healthcare. When conducted in a transparent, science-based, efficient, accountable, and predictable manner, it can help ensure access to quality products that patients need. • Several factors determine access to medicines, including treatment policy, pr...
Article
Full-text available
Access to essential medicines is a key pillar of any health system seeking to deliver universal health coverage. Science-based, independent regulation of medical products is a critical part of ensuring that only quality essential medicines reach the patients who need them. • In this article, we explore the progress the East African Community's Medi...
Article
Full-text available
• The East African Community (EAC)’s Medicines Regulatory Harmonization (MRH) initiative was created to improve access to quality, safe medicines in the region by simplifying the regulatory process while maintaining a high level of rigor. Building on lessons learned since its launch in 2012, the EAC MRH initiative has created a Roadmap for the Futu...
Article
Full-text available
Background: Gene drive mosquitoes have been proposed as a possible means to reduce the transmission of malaria in Africa. Because this technology has no prior use-history at this time, environmental risk assessments for gene drive mosquitoes will benefit from problem formulation-an organized and ordered process to identify protection goals and pot...
Article
Full-text available
The New Partnership for Africa’s Development (NEPAD) Agency recognizes that Africa is in a period of transition and that this demands exploring and harnessing safe advances made in science-based innovations including modern biotechnology. To advance the science of biotechnology in Africa effectively, while at the same time safeguarding human health...

Citations

... [5] There are scarce data on NAFLD in populations living with HIV in sub-Saharan Africa, although rates of obesity, hypertension, dyslipidemia, and impaired glucose tolerance and diabetes are rising in the region. [6,7] Two studies from South Africa investigated selected patients with HIV who had undergone a liver biopsy for various care indications and reported liver steatosis in 19% and 28%, respectively. [8,9] In three studies from Western Africa, the prevalence of liver steatosis by liver ultrasound scan ranged between 13% and 28%. ...
... The health effects of GM crops remain an ethical issue that needs to be investigated due to lack of direct studies on the human health effects and the consumption of GM crops (Garcia-Alonso et al., 2022). The possible solutions towards the health effects of GM crops are the constant regulation of these crops through different biosafety testing and risk assessment by health authorities before consumption (Akinbo et al., 2021). The biosafety testing of GM crops should consider the standard that foods developed from GM plants are intended to be as safe as genetically similar varieties of non-GM plants. ...
... Decision to either regulate or not to regulate the genome edited crops mainly depend on the type of regulatory system that already exists in a country. A recent review provides an update on the regulatory status of new breeding techniques and biosafety approaches in select countries (Obukosia et al., 2020). Nevertheless, with the evolving regulatory framework on genome editing, certain crops have surpassed the regulations to be now under field trial or on the road to commercialization (Figure 2). ...
... Study participants were distributed into three categories; Generics (foreign); that is, applicants who manufacture generic medicines outside of the EAC region, Generics (local); that is, applicants who manufacture generic medicines within the EAC region, and Innovators; that is, applicants who submitted applications for registration of innovator medicines. During the period of study (2015)(2016)(2017)(2018)(2019)(2020)(2021), there were no local innovators that submitted applications for innovator medicines for registration. ...
... However, a study on Medicines Regulation in Africa has shown that most NMRAs in Africa have little capacity to perform all key regulatory functions [9]. In East African Community, SF medicines have been reported in all member states [10]. ...
... The attainment of International Standard (ISO) certification especially ISO-9001 Quality management systems-Requirements by the National Medicines Regulatory Authority is an indicator of a well-functioning regulatory authority [20]. Interestingly, the management has appointed QMS focal persons in each division/unit. ...
... When introduced into both small and large cages of laboratory populations of the malaria mosquito vector Anopheles gambiae, the transgene increases rapidly in frequency, ultimately causing those populations to collapse [31,74]. Drawing on protection goals identified from a series of consultative workshops in Africa [38], problem formulation as a first stage in an ERA (see Box 1) was used for simulated investigational releases of the dsxF CRISPRh transgene carrying mosquito in West Africa [21,48], where the transgene would be expected to act as a non-localized, self-sustaining gene drive. Plausible pathways to potential harm were developed that described the cause-effect chain of events that could lead to 46 discrete potential harms, such as increased disease transmission in humans or reduced ecosystem services [21]. ...
... It has received much attention from many different groups that are associated with gene drives. Efforts at public consultations, particularly in Africa, have been conducted in four regions by the African Union Development Agency-New Partnership for Africa's Development (Glover et al. 2018;Teem et al. 2019), and with stakeholder groups by technology developers and other researchers Finda et al. 2020;MacDonald et al. 2020;Hartley 2021;Thizy et al. 2021;de Graeff et al. 2021). 35 GMO is synonymous with the term "GE organism used in this paper. ...
... Although an NRA or an administrative unit performing some or all expected NRA functions exists in all African countries (with the exception of Sahrawi Republic), only 7% of NRAs in Africa have moderately developed capacity to undertake medicine regulatory functions and over 90% have minimal-to-no capacity [11]. African NRAs are reported to lack competent regulatory professionals, have high staff turnover, inadequate staffing numbers relative to the high workload, low diversity of scientific expertise, perennial backlogs, limited financial resources, poor regulatory infrastructure and they face challenges when they attempt to collaborate with other NRAs in the region [4,5,8,9,[12][13][14][15][16][17][18][19][20][21][22][23]. ...